Medicare price talks defended by DoJ
Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
Could the Trump Administration Change the Medicare Drug Price Negotiation Program?
CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
Determining the various costs of Medicare can be confusing. There are annual deductibles, monthly premiums and doctor visit ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
Older Americans have ways to protect against high out-of-pocket health care costs, but it’s important to understand the trade ...
Medicare Advantage plans, commonly referred to as Medicare Part C, are health insurance plans offered by Medicare-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback